Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6074259 | 0.74 | ALDH1A1 (0.44) | RXRAERN1MAPTKDM4EALDH1A1 | |
| SCHEMBL6074455 | 0.72 | BACE1 (0.34) | KDM4EALDH1A1 | |
| SCHEMBL5791971 | 0.67 | RXRA (0.49) | RXRA | |
| SCHEMBL6073600 | 0.63 | LMNA (0.51) | MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL15726961 | 0.62 | PTGS1 (0.38) | RXRAALDH1A1 | |
| SCHEMBL18131771 | 0.62 | ALDH1A1 (0.52) | ERN1MAPTKDM4EALDH1A1CYP3A4 | |
| SCHEMBL31335743 | 0.61 | ERN1 (0.43) | ERN1KDM4EALDH1A1 | |
| SCHEMBL23011959 | 0.61 | MAP3K5 (0.47) | RXRAALDH1A1ALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL28412796 | 0.61 | ALDH1A1 (0.50) | ERN1MAPTKDM4EALDH1A1CYP3A4 | |
| SCHEMBL746009 | 0.61 | ERN1 (0.50) | ERN1KDM4EMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119207-B2 | Benzoamide piperidine containing compounds and related compounds | PFIZER INC (US) | 2006-10-10 | — | — | US | disclosed |
| US-20030087925-A1 | Benzoamide piperidine containing compounds and related compounds | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
| EP-1272484-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001077100-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087925-A1 | Benzoamide piperidine containing compounds and related compounds | TACR1, VIPR1, VIPR2 | RXRA 3166/4885ERN1 2716/4885MAPT 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.